Takeda Pharmaceutical Company Ltd
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
A Comparative Single-Dose Pharmacokinetic (PK) and Safety Study of Azilsartan Medoxomil in Children With Hypertension and in Healthy Adults
- First Posted Date
- 2010-03-02
- Last Posted Date
- 2014-07-25
- Lead Sponsor
- Takeda
- Target Recruit Count
- 29
- Registration Number
- NCT01078376
Febuxostat Versus Allopurinol or Placebo in Patients With Hyperuricosuria and Calcium Oxalate Stones
Phase 2
Completed
- Conditions
- HyperuricosuriaKidney Stones
- Interventions
- First Posted Date
- 2010-03-01
- Last Posted Date
- 2013-02-15
- Lead Sponsor
- Takeda
- Target Recruit Count
- 99
- Registration Number
- NCT01077284
Instanyl® Non-Interventional Study
Completed
- Conditions
- Breakthrough Cancer Pain
- First Posted Date
- 2010-01-11
- Last Posted Date
- 2012-10-29
- Lead Sponsor
- Takeda
- Target Recruit Count
- 309
- Registration Number
- NCT01045603
- Locations
- 🇬🇧
Investigational site, Wiltshire, United Kingdom
Study to Evaluate the Pharmacokinetics and Safety of Dexlansoprazole in Pediatric Subjects With Symptomatic Gastroesophageal Reflux Disease
- First Posted Date
- 2010-01-08
- Last Posted Date
- 2012-04-05
- Lead Sponsor
- Takeda
- Target Recruit Count
- 36
- Registration Number
- NCT01045096
Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.
Phase 3
Completed
- Conditions
- Essential Hypertension
- Interventions
- First Posted Date
- 2009-12-16
- Last Posted Date
- 2012-02-07
- Lead Sponsor
- Takeda
- Target Recruit Count
- 1071
- Registration Number
- NCT01033071
Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2009-12-02
- Last Posted Date
- 2013-03-26
- Lead Sponsor
- Takeda
- Target Recruit Count
- 784
- Registration Number
- NCT01023581
Efficacy and Safety of Candesartan Cilexetil Plus Hydrochlorothiazide in Subjects With Severe Hypertension
Phase 4
Completed
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2009-11-13
- Last Posted Date
- 2010-07-14
- Lead Sponsor
- Takeda
- Target Recruit Count
- 107
- Registration Number
- NCT01012479
Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcinoma
Phase 3
Completed
- Conditions
- Adenocarcinoma, Prostate
- Interventions
- First Posted Date
- 2009-11-11
- Last Posted Date
- 2015-07-30
- Lead Sponsor
- Takeda
- Target Recruit Count
- 311
- Registration Number
- NCT01011751
- Locations
- 🇫🇷
Professor Jacques IRANI, Poitiers, France
Efficacy and Safety of TAK-875 in Subjects With Type 2 Diabetes Mellitus
Phase 2
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2009-11-03
- Last Posted Date
- 2016-04-13
- Lead Sponsor
- Takeda
- Target Recruit Count
- 426
- Registration Number
- NCT01007097
Safety and Tolerability of Azilsartan Medoxomil Plus Chlorthalidone Compared to Olmesartan Medoxomil Plus Hydrochlorothiazide in Participants With Essential Hypertension
Phase 3
Completed
- Conditions
- Essential Hypertension
- Interventions
- First Posted Date
- 2009-10-16
- Last Posted Date
- 2012-11-12
- Lead Sponsor
- Takeda
- Target Recruit Count
- 837
- Registration Number
- NCT00996281
© Copyright 2025. All Rights Reserved by MedPath